Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.
Leary A, Le Tourneau C, Varga A, Sablin MP, Gomez-Roca C, Guilbaud N, Petain A, Pavlyuk M, Delord JP. Leary A, et al. Among authors: pavlyuk m. Invest New Drugs. 2019 Aug;37(4):693-701. doi: 10.1007/s10637-018-0688-4. Epub 2018 Dec 14. Invest New Drugs. 2019. PMID: 30547316 Free PMC article. Clinical Trial.
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X. Fouquet G, et al. Among authors: pavlyuk m. Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8. Oncotarget. 2018. PMID: 29844860 Free PMC article.
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Pettengell R, Sebban C, Zinzani PL, Derigs HG, Kravchenko S, Singer JW, Theocharous P, Wang L, Pavlyuk M, Makhloufi KM, Coiffier B. Pettengell R, et al. Among authors: pavlyuk m. Br J Haematol. 2016 Sep;174(5):692-9. doi: 10.1111/bjh.14101. Epub 2016 Apr 26. Br J Haematol. 2016. PMID: 27118109 Free PMC article. Clinical Trial.
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Hardy-Bessard AC, Delva R, Pivot X, Espié M, Dalenc F, Coulon Sfairi MA, Monnier A, Serin D, Veyret C, Lortholary A, Pavlyuk M, Kockler L, Pierga JY. Hardy-Bessard AC, et al. Among authors: pavlyuk m. Bull Cancer. 2012 Jun;99(6):609-18. doi: 10.1684/bdc.2012.1586. Bull Cancer. 2012. PMID: 22665515 Free article. Clinical Trial. French.
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Pierga JY, et al. Among authors: pavlyuk m. Lancet Oncol. 2012 Apr;13(4):375-84. doi: 10.1016/S1470-2045(12)70049-9. Epub 2012 Feb 28. Lancet Oncol. 2012. PMID: 22377126 Clinical Trial.